Abstract
Reporter-expressing recombinant severe acute respiratory syndrome coronavirus 2 (rSARS-CoV-2) represents an excellent tool to understand the biology of and ease studying viral infections in vitro and in vivo. The broad range of applications of reporter-expressing recombinant viruses is due to the facilitated expression of fluorescence or bioluminescence readouts. In this chapter, we describe a detailed protocol on the generation of rSARS-CoV-2 expressing Venus, mCherry, and NLuc that represents a valid surrogate to track viral infections.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Huang C et al (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395(10223):497–506
Roberts DL, Rossman JS, Jaric I (2021) Dating first cases of COVID-19. PLoS Pathog 17(6):e1009620
Coronaviridae Study Group of the International Committee on Taxonomy of, V (2020) The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol 5(4):536–544
Harvey WT et al (2021) SARS-CoV-2 variants, spike mutations and immune escape. Nat Rev Microbiol 19:409
Scialo F et al (2021) SARS-CoV-2: one year in the pandemic. What have we learned, the new vaccine era and the threat of SARS-CoV-2 variants. Biomedicine 9(6):611
Sotrovimab (2006) Drugs and lactation database (LactMed). National Library of Medicine (US), Bethesda
Ledford H (2021) COVID antibody treatments show promise for preventing severe disease. Nature 591(7851):513–514
Tuccori M et al (2021) An overview of the preclinical discovery and development of bamlanivimab for the treatment of novel coronavirus infection (COVID-19): reasons for limited clinical use and lessons for the future. Expert Opin Drug Discov 16:1403
Phan AT et al (2021) Emergent inpatient administration of Casirivimab and Imdevimab antibody Cocktail for the treatment of COVID-19 pneumonia. Cureus 13(5):e15280
O'Brien MP et al (2021) Subcutaneous REGEN-COV antibody combination in early SARS-CoV-2 infection. medRxiv 1–38
Skowronski DM, De Serres G (2021) Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 384(16):1576–1577
Oliver SE et al (2020) The Advisory Committee on immunization practices' interim recommendation for use of Pfizer-BioNTech COVID-19 vaccine - United States, December 2020. MMWR Morb Mortal Wkly Rep 69(50):1922–1924
Nassar M et al (2021) COVID-19 vaccine-induced myocarditis: case report with literature review. Diab Metabol Syndr 15(5):102205–102205
Naqvi AA et al (2020) Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: structural genomics approach. BBA-Mol Basis Dis 1866(10):165878
Finkel Y et al (2021) The coding capacity of SARS-CoV-2. Nature 589(7840):125–U254
Belouzard S et al (2012) Mechanisms of coronavirus cell entry mediated by the viral spike protein. Viruses 4(6):1011–1033
Shang J et al (2020) Cell entry mechanisms of SARS-CoV-2. Proc Natl Acad Sci U S A 117(21):11727–11734
Ye Y, Hogue BG (2007) Role of the coronavirus E viroporin protein transmembrane domain in virus assembly. J Virol 81(7):3597–3607
Satarker S, Nampoothiri M (2020) Structural proteins in severe acute respiratory syndrome Coronavirus-2. Arch Med Res 51(6):482–491
Yadav R et al (2021) Role of structural and non-structural proteins and therapeutic targets of SARS-CoV-2 for COVID-19. Cell 10(4):821
Snijder EJ, Decroly E, Ziebuhr J (2016) The nonstructural proteins directing coronavirus RNA synthesis and processing. Adv Virus Res 96:59–126
Raj R (2021) Analysis of non-structural proteins, NSPs of SARS-CoV-2 as targets for computational drug designing. Biochem Biophys Rep 25:100847
Liu DX et al (2014) Accessory proteins of SARS-CoV and other coronaviruses. Antivir Res 109:97–109
Michel CJ et al (2020) Characterization of accessory genes in coronavirus genomes. Virol J 17(1):131
Almazán F et al (2014) Coronavirus reverse genetic systems: infectious clones and replicons. Virus Res 189:262–270
Xie X et al (2020) An infectious cDNA clone of SARS-CoV-2. Cell Host Microbe 27(5):841–848.e3
Yount B et al (2002) Systematic assembly of a full-length infectious cDNA of mouse hepatitis virus strain A59. J Virol 76(21):11065–11078
Hou YJ et al (2020) SARS-CoV-2 reverse genetics reveals a variable infection gradient in the respiratory tract. Cell 182(2):429–446.e14
Shizuya H et al (1992) Cloning and stable maintenance of 300-kilobase-pair fragments of human DNA in Escherichia coli using an F-factor-based vector. Proc Natl Acad Sci U S A 89(18):8794–8797
Avila-Perez G et al (2018) Reverse genetic approaches for the generation of recombinant Zika virus. Viruses 10(11):597
St-Jean JR et al (2006) Recovery of a neurovirulent human coronavirus OC43 from an infectious cDNA clone. J Virol 80(7):3670–3674
Ye C et al (2020) Rescue of SARS-CoV-2 from a single bacterial artificial chromosome. MBio 11, e02168–02120
Ye C et al (2021) Visualization of SARS-CoV-2 infection dynamic. bioRxiv 2021.06.03.446942
Chiem K et al (2021) A bifluorescent-based assay for the identification of neutralizing antibodies against SARS-CoV-2 variants of concern in vitro and in vivo. bioRxiv 2021.06.28.450214
Chiem K et al (2021) Generation and characterization of recombinant SARS-CoV-2 expressing reporter genes. J Virol 95:e02209
Chiem K et al (2019) A Luciferase-fluorescent reporter influenza virus for live imaging and quantification of viral infection. J Vis Exp (150), e59890
Zhao H et al (2005) Emission spectra of bioluminescent reporters and interaction with mammalian tissue determine the sensitivity of detection in vivo. J Biomed Opt 10(4):41210
Shaner NC, Steinbach PA, Tsien RY (2005) A guide to choosing fluorescent proteins. Nat Methods 2(12):905–909
Nogales A et al (2019) A novel fluorescent and bioluminescent Bireporter Influenza A virus to evaluate viral infections. J Virol 93(10):e00032
Nogales A et al (2016) Replication-competent fluorescent-expressing influenza B virus. Virus Res 213:69–81
Welsh DK, Noguchi T (2012) Cellular bioluminescence imaging. Cold Spring Harb Protoc 2012(8):pdb.top070607
Tran V et al (2013) Highly sensitive real-time in vivo imaging of an influenza reporter virus reveals dynamics of replication and spread. J Virol 87(24):13321–13329
Schoggins JW et al (2012) Dengue reporter viruses reveal viral dynamics in interferon receptor-deficient mice and sensitivity to interferon effectors in vitro. Proc Natl Acad Sci U S A 109(36):14610–14615
Luker GD et al (2002) Noninvasive bioluminescence imaging of herpes simplex virus type 1 infection and therapy in living mice. J Virol 76(23):12149–12161
Roehrig JT, Hombach J, Barrett AD (2008) Guidelines for plaque-reduction neutralization testing of human antibodies to dengue viruses. Viral Immunol 21(2):123–132
Bohning K et al (2021) A high throughput reporter virus particle microneutralization assay for quantitation of Zika virus neutralizing antibodies in multiple species. PLoS One 16(4):e0250516
Liu SL et al (2020) Single-virus tracking: from imaging methodologies to virological applications. Chem Rev 120(3):1936–1979
Pahmeier F et al (2021) A versatile reporter system to monitor virus-infected cells and its application to dengue virus and SARS-CoV-2. J Virol 95(4):e01715
Fiege JK, Langlois RA (2015) Investigating influenza A virus infection: tools to track infection and limit tropism. J Virol 89(12):6167–6170
Garg H et al (2017) Development of virus-like-particle vaccine and reporter assay for Zika virus. J Virol 91(20):e00834
Al Ali S et al (2016) Use of reporter genes in the generation of vaccinia virus-derived vectors. Viruses 8(5):134
Islam MK et al (2016) High-throughput screening using a whole-cell virus replication reporter gene assay to identify inhibitory compounds against Rift Valley fever virus infection. J Biomol Screen 21(4):354–362
Fischl W, Bartenschlager R (2013) High-throughput screening using dengue virus reporter genomes. In: Gong EY (ed) Antiviral methods and protocols. Humana Press, Totowa, pp 205–219
Froggatt Heather M et al (2020) Development of a fluorescence-based, high-throughput SARS-CoV-2 3CLpro reporter assay. J Virol 94(22):e01265–e01220
Acknowledgments
We would like to thank the members at Texas Biomedical Research Institute for their efforts in keeping them fully operational during the COVID-19 pandemic and the Institutional Biosafety Committee at Texas Biomedical Research Institute for reviewing our protocols in a time-efficient manner. SARS-CoV-2 research in the Martinez-Sobrido’s laboratory is currently supported by the NIAID/NIH grants RO1AI161363-01, RO1AI161175-01A1, and R43AI165089-01; the Department of Defense (DoD) grants W81XWH2110095 and W81XWH2110103; the San Antonio Partnership for Precision Therapeutic; the Texas Biomedical Research Institute Forum; the University of Texas Health Science Center at San Antonio; the San Antonio Medical Foundation; and the Center for Research on Influenza Pathogenesis and Transmission (CRIPT), a NIAID-funded Center of Excellence for Influenza Research and Response (CEIRR, contract # 75N93021C00014).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Morales Vasquez, D., Chiem, K., Ye, C., Martinez-Sobrido, L. (2022). Bioluminescent and Fluorescent Reporter-Expressing Recombinant SARS-CoV-2. In: Kim, SB. (eds) Bioluminescence. Methods in Molecular Biology, vol 2524. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-2453-1_18
Download citation
DOI: https://doi.org/10.1007/978-1-0716-2453-1_18
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-2452-4
Online ISBN: 978-1-0716-2453-1
eBook Packages: Springer Protocols